Global Yellow Fever Vaccine Market Size Emerging Trends, New Growth Opportunities Status 2024-2032

Yellow Fever Vaccine Market Size And Forecast

Yellow Fever Vaccine Market size was valued at USD 144.87 Million in 2024 and is projected to reach USD 218.64 Million by 2031, growing at a CAGR of 5.28% from 2024 to 2031.

The Yellow Fever Vaccine Market is growing thanks to increased efforts from the World Health Organization and UNICEF. The market for yellow fever treatment is driven by long-term agreements with manufacturers for vaccine and routine programs, as well as emergency and preventive efforts. The Global Yellow Fever Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Yellow Fever Vaccine Market Definition

Yellow fever vaccine is a live-attenuated virus formulation that is exceptionally successful in providing protection to those who get it. This vaccination is recommended for yellow fever-endemic areas, and it may be needed for admission into some countries. It is only necessary to administer a single dose of vaccine subcutaneously. For patients who received their first dose while HIV-positive or pregnant, a 10-year gap is recommended before receiving a booster dose. Boosters are not normally suggested, although they may be required every 10 years depending on the location, despite the fact that the vast majority of people retain immunity for much longer than that. Children under the age of six months appear to be at the greatest risk of severe neurotropic reactions, hence vaccines are not recommended for them.

Anaphylactic hypersensitivity to eggs, as well as immune-compromised states, are other contraindications. Infants should not be vaccinated until they are 9 months old, if at all possible. Although pregnancy is not an absolute contraindication, it is recommended that the vaccine be administered after the pregnancy is completed, if at all possible. Severe and fatal adverse effects of the yellow fever vaccination (YF-VAX) are uncommon and usually occur after the first dosage. A significant adverse reaction occurs roughly once every 250,000 doses on average. Patients above the age of 60 have a substantially increased risk of severe adverse events.

Live attenuated 17DD or 17D-204 substrain viruses generated in embryonated chicken eggs and processed as lyophilized powder are used in all yellow fever vaccines licensed for distribution. Stabilizer chemicals and salt concentration differ amongst vaccines. Others are reconstituted with saline solution and contain sodium chloride and buffer salts. Vaccine expiration dates vary, but all must be stored at 2°C to 8°C at the point of use and used within 1 hour of reconstitution. Reconstituted vaccine, on the other hand, can be utilized throughout an 8-hour workday if it is kept on ice for use in mass vaccination campaigns and the EPI. Vaccines come in single-dose and multidose packages that can hold up to 20 doses each.

In most cases, isolation of the vaccination virus and histopathological changes establish a causal relationship; in cases where specimens are lacking, the temporal association and clinical similarities make a causal association likely. Yellow fever vaccine can be given at the same time as commercially available immunoglobulin, as well as inactivated vaccines. There are no studies that show that the yellow fever vaccine can be given at the same time as other inactivated vaccinations. Injectable or nasally administered live vaccines that are not given on the same day as the yellow fever vaccine should be separated by at least 4 weeks to reduce the chance of interfering. Oral Ty21a typhoid vaccine, on the other hand, can be given before or after the yellow fever vaccination at any time.

Global Yellow Fever Vaccine Market Overview

Over the projected period, the global market for yellow fever treatment is expected to grow at a high rate. The rising prevalence of yellow fever disease, which is carried easily by mosquitoes, is expected to boost demand for yellow fever treatment and propel the worldwide Yellow Fever Vaccine Market forward over the forecast period. Increased yellow fever occurrence, unclean lifestyles, and increased public awareness of yellow fever therapy The market for Yellow Fever vaccines is driven by improving healthcare infrastructure in emerging nations such as Brazil and a rise in the number of travelers visiting endemic countries. The Yellow Fever Vaccine Market’s growth is restrained by a lack of supply to match the rising demand. The yellow fever vaccine is safe, inexpensive, and provides lifelong immunity from yellow fever virus infection, all of which are expected to drive the worldwide Yellow Fever Vaccine Market forward. The WHO’s rigorous immunization restrictions and strong recommendations for anybody older than 9 months living in a disease-prone area.

The World Health Organization also recommends yellow fever vaccination for all tourists visiting places where yellow fever is a danger, which is expected to boost demand for yellow fever vaccines and drive market growth. The long-term growth of the worldwide Yellow Fever Vaccine Market is predicted to be fueled by continuing research and development initiatives in the treatment of yellow fever and related diseases. However, potential side effects of yellow fever vaccination, such as headache, muscular joint pain, swelling, soreness, and body aches, may restrict the demand for yellow fever treatment and limit global market expansion. Over the projection period, supply-side infrastructure bottlenecks such as standardized diagnostic practice, surveillance, and vaccine storage cold chains may have an impact on the worldwide Yellow Fever Vaccine Market.

Global Yellow Fever Vaccine Market: Segmentation Analysis

The Global Yellow Fever Vaccine Market is Segmented on the basis of End User, Treatment Type, and Geography.

Yellow Fever Vaccine Market, By End User

• Hospitals
• Point of Care Centers
• Diagnostic Centers
• Others

Based on End User, the market is segmented into Hospitals, Point of Care Centers, Diagnostic Centers, and Others. Due to an increase in the number of yellow fever vaccinations and increased vaccination awareness among people traveling to endemic countries such as Africa and Latin America, hospitals account for the greatest proportion of the end-user market. It’s also because outpatient department or OPD patients have ease of access to prescription drugs. During the predicted period, diagnostic centers are expected to increase quickly.

Yellow Fever Vaccine Market, By Treatment Type

• Pain Management Drugs
• Oral Rehydration

Based on Treatment Type, the market is segmented into Pain Management Drugs and Oral Rehydration. Oral Rehydration Drugs are the dominating segment in the market as dehydration is one of the most common symptoms of yellow fever, and is the first measure towards the treatment.

Yellow Fever Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on regional analysis, the Global Yellow Fever Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. In terms of revenue, North America is leading the Yellow Fever Vaccine Market, followed by Europe. The United States accounts for a significant portion of the market in the region. Emerging markets such as the Asia Pacific and Latin America are predicted to grow rapidly during the projection period. An increase in the prevalence of yellow fever, the expansion of the healthcare business, and increased government expenditure to construct healthcare infrastructure are all factors contributing to market expansion in these regions. Due to growing knowledge of yellow fever disease